Stay updated on CLR 131 Dose Escalation in Pediatric Malignancy Clinical Trial
Sign up to get notified when there's something new on the CLR 131 Dose Escalation in Pediatric Malignancy Clinical Trial page.

Latest updates to the CLR 131 Dose Escalation in Pediatric Malignancy Clinical Trial page
- CheckyesterdayChange DetectedA UI/layout refresh was applied. Core study details such as eligibility criteria, primary/secondary outcomes, and participating sites appear unchanged.SummaryDifference0.1%

- Check8 days agoChange DetectedScreenshots show no detectable differences; the page content and layout appear unchanged. All listed sections and study details remain the same between images.SummaryDifference0.1%

- Check15 days agoChange DetectedUI/layout refresh observed with no changes to core study data. Essential study sections such as eligibility, outcomes, and locations remain the same.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded the CLOVER-2 dose-escalation study title focusing on pediatric solid tumors, including Rhabdomyosarcoma, and updated the revision to v3.5.0. Replaced the previous broader CLOVER-2 description with the new title and scope.SummaryDifference0.5%

- Check30 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check37 days agoChange DetectedUI tweaks and updated timestamps observed; core study details remain unchanged.SummaryDifference0.1%

Stay in the know with updates to CLR 131 Dose Escalation in Pediatric Malignancy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CLR 131 Dose Escalation in Pediatric Malignancy Clinical Trial page.